These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 25172241)
1. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review. Danieli MG; Gelardi C; Pedini V; Moretti R; Gabrielli A; Logullo F Autoimmun Rev; 2014 Dec; 13(12):1182-8. PubMed ID: 25172241 [TBL] [Abstract][Full Text] [Related]
2. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases. Chen Y; Wang C; Xu F; Ming F; Zhang H Clin Ther; 2019 Oct; 41(10):2112-2136. PubMed ID: 31445679 [TBL] [Abstract][Full Text] [Related]
4. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use. Gandiga PC; Ghetie D; Anderson E; Aggrawal R Curr Rheumatol Rep; 2023 Aug; 25(8):152-168. PubMed ID: 37261663 [TBL] [Abstract][Full Text] [Related]
5. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases. Cherin P; Belizna C; Cartry O; Lascu-Dubos G; de Jaeger C; Delain JC; Crave JC; Hachulla E Autoimmun Rev; 2016 Mar; 15(3):281-6. PubMed ID: 26688441 [TBL] [Abstract][Full Text] [Related]
6. Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world, single-centre experience. Ma Z; Johnson D; Gniadecki R; Ritchie B; Keeling S; Cohen Tervaert JW; Osman M Rheumatology (Oxford); 2024 Aug; 63(8):2118-2122. PubMed ID: 37796840 [TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study. Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648 [TBL] [Abstract][Full Text] [Related]
8. IgPro20, the Polyneuropathy and Treatment with Hizentra Berger M; Harbo T; Cornblath DR; Mielke O Immunotherapy; 2018 Aug; 10(11):919-933. PubMed ID: 29764262 [TBL] [Abstract][Full Text] [Related]
9. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749 [TBL] [Abstract][Full Text] [Related]
10. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J; Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032 [TBL] [Abstract][Full Text] [Related]
11. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. Goyal NA; Karam C; Sheikh KA; Dimachkie MM Muscle Nerve; 2021 Sep; 64(3):243-254. PubMed ID: 34260074 [TBL] [Abstract][Full Text] [Related]
12. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Markvardsen LH; Christiansen I; Jakobsen J Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495 [TBL] [Abstract][Full Text] [Related]
13. Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients. Danieli MG; Verga JU; Mezzanotte C; Terrenato I; Svegliati S; Bilo MB; Moroncini G Front Immunol; 2021; 12():805705. PubMed ID: 35111165 [TBL] [Abstract][Full Text] [Related]
14. Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation? Sanchez-Ramon S; Corbi AL; Fidalgo AG; Dominguez-Soto A Curr Pharm Des; 2016; 22(41):6300-6305. PubMed ID: 27587200 [TBL] [Abstract][Full Text] [Related]
16. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS; Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854 [TBL] [Abstract][Full Text] [Related]
17. A machine learning analysis to predict the response to intravenous and subcutaneous immunoglobulin in inflammatory myopathies. A proposal for a future multi-omics approach in autoimmune diseases. Danieli MG; Tonacci A; Paladini A; Longhi E; Moroncini G; Allegra A; Sansone F; Gangemi S Autoimmun Rev; 2022 Jun; 21(6):103105. PubMed ID: 35452850 [TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin treatment in peripheral nerve disorders--indications, mechanisms of action and side-effects. Hahn AF Curr Opin Neurol; 2000 Oct; 13(5):575-82. PubMed ID: 11073366 [TBL] [Abstract][Full Text] [Related]